Toshimichi Asano
Overview
Explore the profile of Toshimichi Asano including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
87
Citations
511
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Noji T, Takeuchi S, Wada M, Tanaka K, Matsui A, Nakanishi Y, et al.
In Vivo
. 2025 Feb;
39(2):1022-1032.
PMID: 40011006
Background/aim: Hepatectomy with extrahepatic bile duct resection (Hx+EBDR), pancreaticoduodenectomy (PD), and occasionally hepatopancreaticoduodenectomy (HPD) are required for the treatment of advanced gallbladder cancer (GBC). This study aimed to clarify the...
2.
Baba S, Kawasaki T, Hirano S, Nakamura T, Asano T, Okazaki R, et al.
EClinicalMedicine
. 2025 Jan;
78():102936.
PMID: 39764541
Background: Pancreatic cancer is highly aggressive and has a low survival rate primarily due to late-stage diagnosis and the lack of effective early detection methods. We introduce here a novel,...
3.
Hane Y, Tsuchikawa T, Nakamura T, Hatanaka K, Sasaki K, Kawai N, et al.
Neuroendocrinology
. 2025 Jan;
:1-13.
PMID: 39746333
Introduction: Although neuroendocrine neoplasms (NENs) have a good prognosis, distant metastasis remains a crucial prognostic factor. Survivin, a tumor-associated antigen, is overexpressed in several solid tumors, indicating poor prognosis. We...
4.
Zhang H, Tsuchikawa T, Takeuchi S, Deng H, Tanaka K, Matsui A, et al.
World J Surg Oncol
. 2024 Aug;
22(1):209.
PMID: 39097743
Introduction: Survival comparisons among patients with liver metastases from pancreatic and rectal neuroendocrine tumors (NETs) were limited, and the efficacy of observation rules in patients undergoing hepatectomy for neuroendocrine liver...
5.
Zhang H, Tsuchikawa T, Takeuchi S, Hirata K, Tanaka K, Matsui A, et al.
Endocr J
. 2024 Jul;
71(9):873-880.
PMID: 39069495
As novel biomarkers for gastroenteropancreatic neuroendocrine tumors (GEPNET) are in demand, we aimed to validate the clinical value of the NETest in Japanese patients. Between 2021 and 2023, blood and...
6.
Miyazaki D, Shichinohe T, Watanabe Y, Tanaka K, Nakanishi Y, Asano T, et al.
Ann Gastroenterol Surg
. 2024 Jul;
8(4):660-667.
PMID: 38957557
Purpose: Operations for malignant diseases of the bile duct, pancreas, and esophagus are the most invasive gastroenterological surgeries. The frequency of complications after these surgeries is high, which affects the...
7.
Yamamoto H, Nakanishi Y, Mitsuhashi T, Hatanaka Y, Hatanaka K, Nange A, et al.
Ann Surg Oncol
. 2023 Dec;
31(3):2090-2100.
PMID: 38052736
Background: Neutrophil extracellular traps (NETs) are extracellular chromatin structures composed of cytoplasmic, granular, and nuclear components of neutrophils. Recently, NETs have received much attention for their role in tumor biology;...
8.
Aoki Y, Noji T, Tanaka K, Matsui A, Nakanishi Y, Asano T, et al.
Langenbecks Arch Surg
. 2023 Nov;
408(1):430.
PMID: 37938415
Purpose: Recently, systemic inflammatory responses (SIR) have been shown to play a pivotal role in the development and progression of cancer. We previously reported that four factors, serum carcinoembryonic antigen...
9.
Yoshimi Y, Noji T, Okamura K, Tanaka K, Matsui A, Nakanishi Y, et al.
Ann Surg Oncol
. 2023 Oct;
31(1):90-96.
PMID: 37899414
Background: Cancer-free resection (R0) is one of the most important factors for the long-term survival of biliary carcinoma. For some patients with widespread invasive cancer located between the hilar and...
10.
Oba M, Nakanishi Y, Mitsuhashi T, Sasaki K, Hatanaka K, Sasaki M, et al.
Cancers (Basel)
. 2023 Mar;
15(6).
PMID: 36980764
The epithelial-mesenchymal transition (EMT) contributes to the metastatic cascade in various tumors. C-C chemokine receptor 7 (CCR7) interacts with its ligand, chemokine (C-C motif) ligand 19 (CCL19), to promote EMT....